Research across Cancer
Related studies from across the Cancer family.
HITHOC with cytoreductive surgery improves survival in pleural mesothelioma without raising early postoperative risk
Heat treatment shows survival benefit for pleural mesothelioma patients
A meta-analysis of 6 studies (n=1060) found that adding hyperthermic intrathoracic chemotherapy (HITHOC) to cytoreductive surgery for pleura…
A new analysis shows that adding heat to chemotherapy during surgery can extend life for people with a rare type of lung cancer.
Extended resection and intensity-modulated radiotherapy managed a rare primary orbit epithelioid sarcoma
Treatment approach for a rare orbit tumor in a young man
This case report describes the diagnosis and management of a 25-year-old male with primary epithelioid sarcoma of the left orbit. The patien…
A 25-year-old man with a rare eye tumor showed no signs of cancer spread after surgery and targeted radiation therapy.
Tumor Treating Fields may disrupt tumor communication and induce conditional BRCAness in malignant pleural mesothelioma
New review explains how Tumor Treating Fields disrupts cancer cell networks in mesothelioma
This review explores the theoretical mechanisms of Tumor Treating Fields (TTFields) in malignant pleural mesothelioma. The authors describe …
A new review explains how Tumor Treating Fields disrupts cancer cell networks and changes the immune environment in malignant pleural mesoth…
Case series describes four clear cell variant papillary thyroid carcinoma cases with NCOA4-RET fusions
Rare Thyroid Cancer Has Unique Genetic Signature
This case series with literature review describes four pathologically confirmed cases of clear cell variant of papillary thyroid carcinoma d…
A rare thyroid cancer type may have a specific genetic cause that doctors can now look for.
Separate molecular profiling of mixed endometrial carcinoma components yields limited prognostic data in a small retrospective cohort
Separate tumor profiling may reveal hidden risks in mixed endometrial cancer
This hypothesis-generating retrospective cohort analysis included 8 patients with mixed endometrial carcinomas (MEEC).
In mixed endometrial cancer, testing each tumor component separately could uncover risk profiles that standard testing misses.
Pemetrexed use associated with disproportionate reporting of blood, endocrine, and renal disorders in FAERS data
Your Lung Cancer Drug May Have Side Effects Not on the Label
This pharmacovigilance study analyzed 27,098 pemetrexed-associated reports in the US FAERS database from 2004 to 2024.
A safety review of over 27,000 reports found that the lung cancer drug pemetrexed may cause side effects not currently listed on its officia…
TVU during cervical screening detects 81.6% of ovarian cancers at stage I in large cohort
Can a routine ultrasound during cervical screening catch ovarian cancer early?
An observational screening study of 483,269 women undergoing cervical cancer screening found that transvaginal ultrasound performed concurre…
A routine ultrasound during cervical checks found 80% of ovarian cancers at the most curable stage in a massive Japanese screening program.
Case report describes diagnostic challenges in bilateral epithelioid sarcoma of the thigh
Imaging tests missed rare cancer in woman with thigh tumors, case report shows
A case report and literature review describes a 47-year-old woman with bilateral thigh masses where ultrasonography and MRI failed to provid…
Common scans missed a rare cancer in a woman with thigh tumors, proving that biopsies are vital when imaging results are unclear.
Nivolumab+ipilimumab shows 5-year OS benefit (14% vs 6%) vs chemo in unresectable pleural mesothelioma
Can immunotherapy help people with advanced mesothelioma live longer? Five-year results show it can
In the 5-year follow-up of CheckMate 743, nivolumab plus ipilimumab demonstrated continued overall survival benefit versus chemotherapy in u…
Five years after starting treatment, 14% of advanced mesothelioma patients survived on immunotherapy versus 6% on chemotherapy, proving last…
Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma
Could This New Drug Offer Hope for Patients with Returning Pleural Mesothelioma?
A Phase II trial evaluates ivonescimab in 38 pleural mesothelioma patients post-immunotherapy/chemotherapy. The study aims for a ≥55% diseas…
Patients with returning pleural mesothelioma may find hope in ivonescimab, a new drug being tested to control stubborn cancer after standard…